landogrozumab   

GtoPdb Ligand ID: 8730

Synonyms: LY-2495655 | LY2495655
Compound class: Antibody
Comment: Landogrozumab is an investigational anti-myostatin, humanized, monoclonal antibody.
Peptide sequences and structural information for this antibody are available from its IMGT/mAb-DB record.
A BLAST protein search using the light and heavy chain variable regions of landogrozumab, identifies 100% matches with sequences patented in US7632499 B2 [2], and point towards clone 3-74/C1E4, as a preferred embodiment, taken forward for further anaylsis.
References
1. Bogdanovich S, McNally EM, Khurana TS. (2008)
Myostatin blockade improves function but not histopathology in a murine model of limb-girdle muscular dystrophy 2C.
Muscle Nerve, 37 (3): 308-16. [PMID:18041051]
2. Davies J, Jones BE, Korytko AI, Mitchell PJ, Smith RC, O'Bryan LM, Wang R. (2009)
Anti-myostatin antibodies.
Patent number: US7632499 B2. Assignee: Eli Lilly And Company. Priority date: 12/10/2005. Publication date: 15/12/2009.
3. Han HQ, Zhou X, Mitch WE, Goldberg AL. (2013)
Myostatin/activin pathway antagonism: molecular basis and therapeutic potential.
Int. J. Biochem. Cell Biol., 45 (10): 2333-47. [PMID:23721881]
4. Smith RC, Lin BK. (2013)
Myostatin inhibitors as therapies for muscle wasting associated with cancer and other disorders.
Curr Opin Support Palliat Care, 7 (4): 352-60. [PMID:24157714]